This region comprises all Asian territories where we sell products, including China. Active trading subsidiaries include those in China, the Philippines, Taiwan and Malaysia with other countries in the region reached via distributors. Sterile Focus Brands are the key contributor to revenue. Our manufacturing facility in India is our primary new product development site.
KEY COUNTRIES AND TERRITORIES
|Eltroxin||Thyroid hormone replacement|
|Fraxiparine||Low molecular weight heparin|
NUMBER OF PERMANENT EMPLOYEES
Number of products launched:
Number of product recalls:
Average staff turnover:
Number of work-related fatalities:
|Total Commercial Pharmaceuticals||5 117||4 457||15|
|Sterile Focus Brands||4 491||3 853||17|
|Manufacturing – API Chemicals||77||113||(32)|
|Total||5 194||4 570||14|
Note: Commercial Pharmaceuticals revenue by customer geography and manufacturing revenue by place of manufacture.
- The Chinese general anaesthesia therapy area consists of inhalation and intravenous products. The propofol market grew 10,6% year-on-year MAT* May 2021.
- The South Korean pharmaceutical market is forecast to grow at a CAGR of 6% between 2019 and 2024, reaching Won24,579 billion by 2024.
Source: China IMS CHPA Report, May 2021.
*MAT = Moving annual total